Presented here is a protocol for Pseudomonas aeruginosa infection and phage therapy application in cystic fibrosis (CF) zebrafish embryos.
Antimicrobial resistance, a major consequence of diagnostic uncertainty and antimicrobial overprescription, is an increasingly recognized cause of severe infections, complications, and mortality worldwide with a huge impact on our society and on the health system. In particular, patients with compromised immune systems or pre-existing and chronic pathologies, such as cystic fibrosis (CF), are subjected to frequent antibiotic treatments to control the infections with the appearance and diffusion of multidrug resistant isolates. Therefore, there is an urgent need to address alternative therapies to counteract bacterial infections. Use of bacteriophages, the natural enemies of bacteria, can be a possible solution. The protocol detailed in this work describes the application of phage therapy against Pseudomonas aeruginosa infection in CF zebrafish embryos. Zebrafish embryos were infected with P. aeruginosa to demonstrate that phage therapy is effective against P. aeruginosa infections as it reduces lethality, bacterial burden and pro-inflammatory immune response in CF embryos.
Phage therapy, the use of the natural enemies of bacteria to fight bacterial infections, is garnering renewed interest as bacterial resistance to antibiotics becomes widespread1,2. This therapy, used for decades in Eastern Europe, could be considered a complementary treatment to antibiotics in curing lung infections in patients with CF and a possible therapeutic alternative for patients infected with bacteria that are resistant to all the currently in use antibiotics2,3. Advantages of antibiotic therapy are that bacteriophages multiply at the infection site, whereas antibiotics are metabolized and eliminated from the body4,5. Indeed, the administration of cocktails of virulent phages isolated in different laboratories has proven to be effective in treating Pseudomonas aeruginosa infections in animal models as different as insects and mammals6,7,8. Phage therapy was also shown to be able to reduce the bacterial burden in burn wounds infected with P. aeruginosa and Escherichia coli in a randomized clinical trial9.
Zebrafish (Danio rerio) has recently emerged as a valuable model to study infections with several pathogens, including P. aeruginosa10,11, Mycobacterium abscessus and Burkolderia cepacia12,13. By microinjecting bacteria directly into the embryo blood circulation14 it is easy to establish a systemic infection that is counteracted by the zebrafish innate immune system, which is evolutionary conserved with neutrophils and macrophage generation similar to the human counterpart. Moreover, during the first month of life, zebrafish embryos lack the adaptive immune response, making them ideal models for studying the innate immunity, which is the critical defense mechanism in human lung infections15. Zebrafish recently emerged as a powerful genetic model system to better understand the CF onset and to develop new pharmacological treatments10,16,17. The CF zebrafish model of cftr knock-down generated with morpholino injection in zebrafish presented a dampened respiratory burst response and reduced neutrophil migration10, while the cftr knock-out leads to impaired internal organ position and the destruction of the exocrine pancreas, a phenotype that mirrors human disease16,17. Of greatest interest was the finding that the P. aeruginosa bacterial burden was significantly higher in cftr-loss-of-function embryos than in controls at 8 hours post-infection (hpi), which parallels the results obtained with mice and human bronchial epithelial cells2,18.
In this work, we demonstrate that phage therapy is effective against P. aeruginosa infections in zebrafish embryos.
Adult zebrafish (Danio rerio) from the AB strain (European Zebrafish Resource Center EZRC) are maintained according to international (EU Directive 2010/63/EU) and national guidelines (Italian decree 4th March 2014, n. 26) on the protection of animals used for scientific purposes. Standard conditions are set in the fish facility with a 14 h of light/10 h dark cycle and tank water temperature at 28° C.
1. Preparation of solutions and tools
2. P. aeruginosa (PAO1) inoculum preparation
3. Phage stock preparation
4. Phage cocktail preparation
5. Collection and preparation of zebrafish embryos for cftr morpholinos microinjection
NOTE: Collect 1-2 cell embryos from wild type zebrafish for cftr morpholinos (cftr-MOs) microinjection.
6. Microinjection of zebrafish embryos with bacteria and phage cocktail
NOTE: To perform a systemic infection, the embryo must have blood circulation that usually starts after 26 hpf.
7. Evaluation of the bacterial burden of embryos injected with PAO1 and phages
8. Evaluation of the lethality of embryos injected with PAO1 and phages
9. Embryo preparation for stereomicroscope time-lapse imaging of GFP+ PAO1 infection
10. Expression analyses of pro-inflammatory cytokines
Results and figures presented here are referred to CF embryos generated through the injection of cftr morpholinos as described previously10 and in step 5. To validate the CF phenotype, the impaired position of internal organs such as heart, liver, and pancreas as previously described17 (Figure 1) were considered. Similar results were obtained in case of the WT embryos as reported in our previous publication19.
Bacterial burden was reduced by phage therapy in CF embryos infected with PAO1. Furthermore, we evaluated the bacterial burden at 8 hpi by homogenizing groups of 15 embryos: the average number of bacteria (cfu/embryo) present in the PAO1 infected embryos was reduced to about 20% after phage administration treatment, thus confirming a less severe infection in the presence of the phage cocktail (Figure 2).
Lethality was reduced by phage therapy in CF embryos infected with GFP+ bacteria PAO1. CF zebrafish embryos at 48 hpf were injected with GFP+ bacteria of the PAO1 strain at a dose that caused 50% lethality after 20 hpi (30 cfu/embryo, Figure 3A). The site of injection was the yolk or the Duct of Cuvier to generate a systemic infection. Phage therapy against PAO1 infection was tested by injecting 2 nL of the equally mixed phage cocktail (300-500 pfu/embryo). The injection was performed at two different time points: 30 min (early) and 7 hours (late) after bacterial injection. In both cases, lethality was reduced at 20 hpi, indicating that phage therapy is effective (Figure 3B).
With live imaging, using a fluorescent stereomicroscope, we also followed the progression of the infection in CF embryos injected with GFP+ PAO1 and showed the efficacy of phage therapy in reducing the spread of fluorescent bacteria over the yolk sac. The CF+PAO1 injected embryo with GFP+ bacteria multiplication at 4, 9, 14 and 18 hpi is shown in the upper side of Figure 4, whereas the CF+PAO1+phages embryo with reduced fluorescence due to phage action against bacteria is shown in the bottom part (Figure 4).
Phage therapy reduced the inflammatory response generated by PAO1 infection in CF embryos. We, also, evaluated the immune response generated by PAO1 and PAO1 + phages injection at 8 hpi. As expected, the expression of the pro-inflammatory cytokines TNF-a and IL-1β analyzed by qPCR techniques was significantly increased following PAO1 injection in comparison to controls, while it was reduced with the co-injection of the phage cocktail (Figure 5A,B).
Figure 1: Generation and validation of CF embryos upon cftr morpholinos (cftr-MOs) injection. (A) Impaired position and looping of the heart in CF injected embryos in comparison to wild-type (WT) embryos. Heart is visualized with cmlc2 expression by in situ hybridization technique. (B) Impaired position of the liver (arrows) and pancreas in CF embryos in comparison to WT. Liver and pancreas are visualized with prox1a expression by in situ hybridization techniques. Scale bars indicate 100 μm. liv: liver; p: pancreas. The figure is reprinted from19 Please click here to view a larger version of this figure.
Figure 2: Bacterial burden in CF embryos infected with PAO1 or PAO1+phages. The relative percentage of cfu/embryo in PAO1+phages vs PAO1 embryos are given. The mean and SD of three independent experiments is reported. The figure is reprinted from19. Please click here to view a larger version of this figure.
Figure 3: Lethality of CF zebrafish embryos infected with PAO1 and with PAO1+phages. (A) Determination of LD50 in 48 hpf zebrafish embryos microinjected with cftr-MO at 1-cell stage (CF embryos) and infected at 48 hpf with 2 nL of a culture of PAO1 containing increasing number of bacteria (cfu/embryo). Lethality of the embryos was observed at 20 hpi. (B) Lethality at 20 hpi of CF embryos infected with PAO1 at 48 hpf and treated with the phage cocktail (PAO1+ Φ). The mean and SD reported are from six and four experiments, respectively, each with 25-40 embryos. Angular transformation was applied to the percentage of lethality and one-way ANOVA followed by Duncan’s test was used. The figure is reprinted from19. Please click here to view a larger version of this figure.
Figure 4: Imaging of the efficacy of phage therapy in zebrafish. Progression of the infection in CF embryos following PAO1 injection (upper embryo) and efficacy of the phage therapy in PAO1+phages injected embryos (bottom embryo) at 4, 9, 14 and 18 hpi. Scale bar indicates 100 microns. The figure is reprinted from19. Please click here to view a larger version of this figure.
Figure 5: Expression of pro- and anti-inflammatory cytokines following PAO1 and PAO+phage administration. Expression levels of the TNF-a (A) and IL-1β genes measured by RT-qPCR at 8 hpi in CF embryos injected with PAO1 and PAO1+Φ at 48 hpf and normalized using the expression of rpl8. The mean and SD of four experiments are reported. Statistical significance was assessed by ANOVA followed by Duncan’s test: for TNF- a (CF) vs (CF+PAO1) p = 0.015*; (CF) vs (CF+PAO1+Φ) p = 0.019*; (CF+PAO1) vs (CF+PAO1+ Φ) p = 0.77 n.s.; for IL-1β (CF) vs (CF+PAO1) p = 0.00014***; (CF) vs (CF+PAO1+ Φ) p = 0.00068***; (CF+PAO1) vs (CF+PAO1+ Φ) p = 0.031*. The figure is reprinted from19. Please click here to view a larger version of this figure.
Solutions | Preparation |
Anaesthetic stock solution 25X | 4 mg/mL of Tricaine in distilled H2O. |
Anaesthetic working solution 1X | dilute in distilled H2O the Tricaine stock solution 25X preparation to reach the 1X concentration (0.16 mg/mL) Tricaine of distilled H2O. |
CsCl d=1.3 | 20.49 g in 50 mL TN |
CsCl d=1.4 | 20.28 g in 50 mL TN |
CsCl d=1.5 | 34.13 g in 50 mL TN |
CsCl d=1.6 | 41.2 g in 50 mL of TN |
E3 embryo medium for zebrafish embryo | 1 L 1of E3 (dilute the 50X stock with distilled H2O) + 200 μl of 0.05% methyl blue . Store at RT. |
E3 embryo medium stock solution (50X) | 73.0 g NaCl, 3.15 g KCl , 9.15 g CaCl2 , and 9.95 g MgSO4 in 5 L of distilled H2O. Store at RT. |
LB agar | 10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, 10 g/L agar |
LB broth | for 1L: 950 mL H2O, 10 g Tryptone, 10 g NaCl, 5 g Yeast extract |
PBST | PBS 1X + Triton X 1% |
Physiological solution | 0.9% NaCl |
Pigmentation blocking stock solution 10X | 0.3 mg/mL phenyl thiourea (PTU) powder in E3 embryo medium for zebrafish embryo |
Pronase stock solution 5X | 5 mg/mL pronase powder in E3 embryo medium for zebrafish embryo |
TN buffer | 10 mM Tris HCl pH 8.0, 150 mM NaCl |
Table 1: Preparation of solutions.
Gene name | Primer sequence |
TNF-alpha Fw | 5’-TGCTTCACGCTCCATAAGACC-3’ |
TNFalpha Rev | 5’-CAAGCCACCTGAAGAAAAGG-3’ |
IL1-beta Fw | 5’-TGGACTTCGCAGCACAAAATG-3’ |
IL1-beta Rev | 5’-CGTTCACTTCACGCTCTTGGATG-3’ |
rpl8 Fw | 5’-CTCCGTCTTCAAAGCCCAT-3’ |
rpl8 Rev | 5’-TCCTTCACGATCCCCTTGAT-3’ |
Table 2: Primers used for RT-qPCR.
In this manuscript, we described the protocol to perform P. aeruginosa (PAO1) infection in zebrafish embryos and how to apply phage therapy with a cocktail of phages previously identified as able to infect PAO1 to resolve it. The use of bacteriophages as an alternative to antibiotic treatments has been of increasing interest since the last few years. This is mainly due to the diffusion of multi-drug resistant (MDR) bacterial infections, which constitute a serious issue for public health. Of course, the scope of this work is limited to the application of phage therapy to an animal model and not to humans. However, we generated a cystic fibrosis zebrafish model with the injection of a morpholino targeting the cftr gene, demonstrating the efficacy of phage therapy also in a pathogenetic model particularly susceptible to P.aeruginosa infection.
It is to note that we could easily achieve phage therapy, as in a previous work, we isolated and characterized different phages able to infect P. aeruginosa both in vitro and in vivo8. This step is fundamental to obtain the antimicrobial activity of the phages. The isolation and characterization of phages able to infect a specific bacterial strain are critical steps of phage therapy application. Indeed, to avoid adverse effects of phages on the animal/human host, it is necessary to use lytic phages instead of those lysogenic. Most importantly, it is necessary to check the phage genomes for the presence of harmful genes as those for antibiotic resistance, virulence and gene transfer.
Phage therapy has already been successfully used in other animal models. We are conscious that zebrafish is not a mammalian model and some effects of phages might be different. However, since zebrafish possess an innate immune system comparable to the human one with a conserved population of neutrophils and macrophages23, we speculate that the data on the immune response could be reproducible in humans. Moreover, zebrafish is well assessed for bacterial infection studies, its use as a tester for phage therapy efficacy might be promising for therapeutic approaches. Indeed, the infection can be systemic if bacteria are injected into the circulation through the Duct of Cuvier, or localized as reported17. We performed both systemic and localized infections and demonstrated that they similarly generated increased lethality and bacterial burden that were both decreased following phage therapy application. Moreover, since GFP+ fluorescent PAO1 bacteria was injected, it was easy to follow the infection at different time points of embryo development confirming the reduction of fluorescent bacteria when phages were injected.
To our knowledge, this is the first description of phage therapy application in zebrafish, with the added value for the demonstration of phages antimicrobial activity against P. aeruginosa in a CF background, that is particularly susceptible to this bacterial infection.
The authors have nothing to disclose.
This work was supported by the Italian Cystic Fibrosis Foundation (FFC#22/2017; Associazione “Gli amici della Ritty" Casnigo and FFC#23/2019; Un respiro in più Onlus La Mano tesa Onlus).
Bacto Agar | BD | 214010 | |
Calcium chloride | Sigma-Aldrich | 10043-52-4 | |
CsCl | Sigma-Aldrich | 289329 | |
Dulbecco's phospate buffered saline PBS | Sigma-Aldrich | D8537 | |
Ethyl 3-aminobenzoate methanesulfonate | Sigma-Aldrich | 886-86-2 | common name tricaine |
Femtojet Micromanipulator | Eppendorf | 5247 | |
Fleming/brown P-97 | Sutter Instrument Company | P-97 | |
LE-Agarose | Sigma-Aldrich | 11685660001 | |
Low Melting Agarose | Sigma-Aldrich | CAS 9012-36-6 | |
Magnesium sulfate | Sigma-Aldrich | 7487-88-9 | |
Methyl Blue | Sigma-Aldrich | 28983-56-4 | |
Microinjection needles | Harvard apparatus | ||
N-Phenylthiourea >=98% | Aldrich-P7629 | 103-85-5 | |
Oligo Morpholino | Gene Tools | designed by the researcher | |
PEG6000 | Calbiochem | 528877 | |
Phenol Red Solution | Sigma-Aldrich | CAS 143-74-B | |
Potassium chloride | Sigma-Aldrich | 7447-40-7 | |
Pronase | Sigma-Aldrich | 9036-06-0 | |
Sodium chloride ACS reagent, ≥99.0% | Sigma-Aldrich | S9888 | |
Stereomicroscope | Leica | S9I | |
Tris HCl | Sigma-Aldrich | T5941 | |
Triton X | Sigma-Aldrich | T9284 | |
Tryptone | Oxoid | LP0042B | |
Yeast extract | Oxoid | LP0021B | |
Z-MOLDS Microinjection | Word Precision Instruments |